Inicio>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> Drug-Linker Conjugates for ADC>>VcMMAE

VcMMAE (Synonyms: MC-VC-PAB-MMAE, Vedotin)

Catalog No.GC37891

VcMMAE (mc-vc-PAB-MMAE) es un conjugado de enlace de fÁrmaco para ADC con una potente actividad antitumoral mediante el uso del agente antimitÓtico, monometil auristatina E (MMAE, un inhibidor de tubulina), unido a través del dipéptido escindible en los lisosomas, valina- citrulina (vc).

Products are for research use only. Not for human use. We do not sell to patients.

VcMMAE Chemical Structure

Cas No.: 646502-53-6

Tamaño Precio Disponibilidad Cantidad
1mg
25,00 $
Disponible
5mg
75,00 $
Disponible
10mg
119,00 $
Disponible
50mg
270,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

VcMMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).

Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].

Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models[2].

[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. [3]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.

Reseñas

Review for VcMMAE

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for VcMMAE

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.